Expression of Prostaglandin E2 Receptors in Acquired Middle Ear Cholesteatoma.

OBJECTIVES: To investigate the expression of prostaglandin E2 receptor subtypes, E-prostanoid (EP) 1-4 receptors, in acquired cholesteatoma and its possible role in the pathologic process of this disorder.
METHODS: Specimens of human acquired cholesteatoma were obtained from 29 patients and 19 skin biopsies of normal external auditory canal were as controls. The mRNA and protein expression of EP receptors was assessed by quantitative real-time polymerase chain reaction, immunohistochemistry and Western blot.
RESULTS: In acquired cholesteatoma, EP1-EP4 receptors were mainly expressed on squamous epithelium and subepithelial infiltrated inflammatory cells. In external auditory canal skin, EP1-EP4 receptors were mainly expressed on squamous epithelium and glandular epithelium. The expression of EP4 receptor on mRNA and protein levels were significant lower in acquired cholesteatoma compared with controls. EP1-EP3 receptors had no significant difference between the experimental and control group.
CONCLUSION: Low expression of EP4 may play a crucial role in the pathologic process of inflammation reaction and bone destruction in acquired cholesteatoma, but not EP1, EP2, or EP3 receptors.

INTRODUCTION

Middle ear cholesteatoma is a mass of keratin-producing squamous epithelium in the middle ear, which has been divided into congenital cholesteatoma and acquired cholesteatoma according to their theoretical mechanism of pathogenesis [1]. Acquired cholesteatoma has a history of primary or secondary otitis media. It is a chronic inflammatory disease usually accompanied with tympanic membrane perforation or inverted cysts and characterized by bone destruction.

The etiology of cholesteatoma is complex and multifactorial. Previous studies suggest the hyperproliferation and bone destruction of cholesteatoma are directly or indirectly related to inflammatory mediators. Cytokines, chemokines, prostaglandins, and leukotrienes which were generated by lymphocytes, monocyte, neutrophils, and keratinocytes in cholesteatoma may cause tissue damage in the chronic inflammatory process [2]. For example, activation of interleukin (IL)-6/JAK/STAT3 signaling pathway played a crucial role in the epithelial hyperplasia of cholesteatoma [3]. Some studies also suggested IL-1α, tumor necrosis factor-α (TNF-α), and prostaglandins are released to stimulate osteoclasts formation and bone resorption in cholesteatoma [4]. However, the exact pathological mechanism of middle ear cholesteatoma is still unclear.

Prostaglandin E2 (PGE2) is one of the most important members of prostaglandin family. It is a well-known inflammatory and bone metabolism mediator, which plays various roles in different types of inflammatory and bone-related disorders through four E-prostanoid (EP) receptors, EP1, EP2, EP3, and EP4. Each EP receptor mediates a specific intracellular signaling pathway to perform different functions. In the acquired cholesteatoma, several researchers found that the concentration of PGE2 in cholesteatoma is significant higher than granulation tissue [5] and PGE2 may promote bone erosion in cholesteatoma [6]. However, EP receptor expression of cholesteatoma has not been reported and it is not yet clear which receptors were involved in the pathological process of cholesteatoma. Therefore, the present study was designed to investigate the expression profiles of EP receptors in acquired cholesteatoma and understand the possible role of EP receptors in the pathological process of this disorder.

MATERIALS AND METHODS

Subjects and specimens

This study was approved by the ethics committee of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (approval No. TJ-C20130312), and was conducted with written informed consent from patients. The cholesteatoma samples from 29 patients (mean age, 28.9 years; range, 3 to 64 years; female, 43.5%) with acquired cholesteatoma were as experimental group and 19 external auditory canal skin specimens (mean age, 25.5 years; range, 3 to 49 years; female, 42.1%) as control group. The diagnoses of acquired cholesteatoma in the experimental group were confirmed by pathologic examination and clinical data. Specimens were collected during the cholesteatoma surgery on a dry ear. Control group were also from the acquired middle ear cholesteatoma patients without inflammation in external auditory canal.

Immunohistochemistry

Specimens were fixed in 4% paraformaldehyde, embedded in paraffin and cut into 4 μm. Hematoxylin-eosin stain was applied to confirm the specimens contained the squamous epithelium and subepithelium. After deparaffinization and rehydration, the tissue sections were treated in a microwave oven for antigen retrieval. Endogenous peroxidase activity was blocked by 3% hydrogen peroxidase. Then, the tissue slides were treated with 5% bovine serum albumin to block nonspecific binding sites. Sections were incubated with polyclonal rabbit antihuman EP receptors (EP1–EP4 at a dilution of 1:100; Cayman Chemical, Ann Arbor, MI, USA) overnight at 4°C. A secondary antibody and a streptavidin-biotin horseradish peroxidase kit (GK600510, Gene Tech, Shanghai, China) were used for immunohistochemical staining. The sections were washed with phosphate buffered saline. The immunoreactions were visualized by using 3,3-diaminobenzidine tetrahydrochloride, which stained positive cells brown. Negative control slides had the same immunohistologic treatment with substitution of the primary antibody with no immune sera of the same species.

Quantitative real-time polymerase chain reaction

Total RNA was obtained from specimens with a RNA extraction kit according to product instructions (Tiangen Biotech, Beijing, China). cDNA was prepared using PrimeScript RT reagent kit with gDNA eraser (Takara Bio Inc., Otsu, Japan). Then quantitative real-time polymerase chain reaction (PCR) was run on LightCycler 480 II (Roche, Basel, Switzerland) using SYBR Premix Ex Taq (Takara Bio Inc.). Primers used for quantitative real-time PCR were show in Table 1. The quantitative real-time PCR reaction condition for EP1–EP4 was 40 cycles, denaturation at 95°C for 10 seconds, annealing at 60°C for 10 seconds, and extension at 72°C for 15 seconds. The expression of the four receptors was normalized to housekeeping gene GAPGH for each sample. Every reaction has three duplicates. Ct value is small enough and similar between the duplicates. Melting curve was analyzed to rule out contamination.

Table 1.

Primer sequences used for real-time PCR amplifications

Primer	Sequence	Amplicon size (bp)	Annealing temperature (°C)
EP1	(F)5´-AGCTTGTCGGTATCATGGTGG-3´	283	60
	(R)5´-AAGAGGCGAAGCAGTTGGC-3´
EP2	(F)5´-CGATGCTCATGCTCTTCGC-3´	126	60
	(R)5´-GGGAGACTGCATAGATGACAGG-3
EP3	(F)5´-CGCCTCAACCACTCCTACAC-3´	107	60
	(R)5´-GACACCGATCCGCAATCCTC-3
EP4	(F)5´-CCGGCGGTGATGTTCATCTT-3´	111	60
	(R)5´-CCCACATACCAGCGTGTAGAA-3
GAPDH	(F)5´-ACTTTGGTATCGTGGAAGGACTCAT-3´	255	60
	(R)5´-GTTTTTCTAGACGGCAGGTCAGG-3

PCR, polymerase chain reaction; EP, E-prostanoid; GAPDH, glyceraldehyde phosphate dehydrogenase.

Western blot

The cholesteatoma and external auditory canal skin tissues were lysed with lysis buffer (RIPA and protease inhibitors) in homogenizers to get total proteins. Quantified protein (40 μg) was mixed with loading buffer, boiled for 5 minutes to denature, subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes. After blocking with 5% nonfat milk in Tris-buffered saline for 2 hours at room temperature, the membranes were incubated with polyclonal rabbit antihuman EP receptors (EP1 at 1:1,000, EP2 at 1:1,200, EP3 at 1:1,500, and EP4 at 1:500; Cayman Chemical) overnight at 4°C. Then the membranes were washed with Tris-buffered saline and incubated with horseradish peroxidase-linked secondary antibodies (1:3,000 dilution; Goodbio, Wuhan, China). The signals were examined by using a chemiluminescent method (Pierce Chemical, Rockford, IL, USA). Protein levels were semiquantified. The target protein was normalized to glyceraldehyde phosphate dehydrogenase. GeneTools 4.0 software (Syngene, Cambridge, UK) was used to quantify protein band intensities.

Statistical analysis

Data were analyzed by Graphpad Prism Software ver. 5.0 (Graphpad Software, San Diego, CA, USA) and SPSS ver. 19.0 (IBM Corp., Armonk, NY, USA). The significant expression differences of the EP1, EP2, EP3, and EP4 receptors between the cholesteatoma and the skin were analyzed with the Mann-Whitney U-test. Statistical significance was concluded at P-value<0.05.

RESULTS

Immunohistochemical staining

The immunohistochemistry staining showed positive reaction of EP1–EP4 receptors in acquired cholesteatoma and skin. EP1–EP4 receptors showed a similar cellular localization in both groups. The four receptors were all positive on squamous epithelium of skin and cholesteatoma. Besides, EP2 and EP3 receptors were also expressed on the blood vessels in acquired cholesteatoma and control subject. There were some differences in EP expression between two groups. In acquired cholesteatoma, EP1–EP4 receptors were expressed on the infiltrated inflammatory cells. In skin, positive reaction of the four receptors were also found on subepithelial gland (Fig. 1).

Fig. 1.

Immunohistochemical localization of the (A-D) EP1–EP4 receptors and (E) negative control (NC) in acquired cholesteatoma (CHOL) and external auditory canal skin (SKIN) (×400). EP2 and EP3 receptors were positive in vascular endothelium (bold arrows). EP1–EP4 receptors were also expressed on and residues of the middle ear mucosa (thin arrows, data EP1 and EP2 not shown). Red arrows showed the inflammatory cells. Brown staining represents positive expression. EP, E-prostanoid.

mRNA expression of EP receptors

We tested the EP receptor subtypes mRNA expression in both groups with quantitative real-time PCR. In comparison with control group, the mRNA expression level of EP4 receptor was significantly lower in cholesteatoma (P=0.016) (Fig. 2). There were no significant differences in mRNA expression level of EP1, EP2, and EP3 receptors between the two groups.

Fig. 2.

Comparison of mRNA expression of EP1, EP2, EP3, and EP4 receptors between external auditory canal skin (SKIN) and cholesteatoma (CHOL). The expression of EP4 receptor, but not EP1–EP3 receptors, was significantly reduced in cholesteatoma. EP, E-prostanoid. *P<0.05.

Protein expression of EP receptor subtypes

Western blot analysis revealed that EP1–EP4 were present in cholesteatoma and the external auditory canal skin at detectable levels. The level of EP4 receptors were significantly downregulated in acquired cholesteatoma specimens compared with controls (P=0.002) (Fig. 3). There was no significant difference in the protein levels of EP1–EP3 receptors between the cholesteatoma and the skin.

Fig. 3.

(A) Representative immunoblots of the four EP receptors and (B) comparison of protein expression of EP receptors between external auditory canal skin (SKIN) and cholesteatoma (CHOL). EP, E-prostanoid; GAPDH, glyceraldehyde phosphate dehydrogenase. *P<0.05.

DISCUSSION

In this study, we first demonstrate the expression profiles of the four EP receptor subtypes in human acquired cholesteatoma and skin of the external acoustic meatus. We found EP1–EP4 were positive on structural cells (epithelium, glands, and/or blood vessels) in external auricular canal skin. As for cholesteatoma, our findings showed that EP receptors were expressed not only on structural cells (epithelium and/or blood vessels) but also on subepithelium inflammatory cells. The different localization of EP1–EP4 receptors between cholesteatoma and skin may be explained by the differences in histopathology because of the lack of glandular structure in cholesteatoma. More importantly, amounts of infiltrating inflammatory cells play a crucial role in the inflammatory reaction of cholesteatoma as described [2]. The differences in cellular distributions of EP receptors maybe link with aggressive and destructive pathological processes in cholesteatoma.

Our results showed that the mRNA and protein expression of EP4 receptor was significantly decreased in cholesteatoma in comparison with the skin. EP4 receptor is involved in various physiological and pathological processes. For example, EP4 receptor mediated vascular relaxation [7] and the closure of ductus arteriosus [8]. Most studies demonstrated that EP4 mainly played a crucial anti-inflammatory role in inflammatory diseases [9-11]. PGE2 suppressed expression of various inflammatory chemokines including macrophage inflammatory protein-1α and -1β, monocyte chemoattractant protein-1, IL-8, TNF-α, and interferon-γ in human macrophages by EP4 receptor in atherosclerosis [9]. EP4-selective antagonist induced obvious proliferation of CD4+ T cells and inhibited the recovery of colonitis [10]. Structural cells (epithelium and vascular endothelium), local cells such as keratinocytes and mast cells as well as infiltrating inflammatory cells in cholesteatoma are the sources of a large number of proinflammatory factors including chemokines, cytokines, and prostaglandins [2]. Excess proinflammatory mediators cause inflammatory lesions and contribute to destruction of the bone and ossicles. Based on this knowledge, we consider that the reduced expression of EP4 receptors may aggravate the inflammation response of cholesteatoma due to its decreased anti-inflammatory effect.

One of the most distinct characteristics of cholesteatoma is bone destruction, which may cause auditory ossicles and surrounding bone resorption, leading to the serious consequences of hearing loss, vestibular dysfunction, facial paralysis, intracranial complications, and so on. Bone metabolism is up to the balance of osteoblasts and osteoclasts. PGE2 is one of the most important mediators involved in bone metabolism; several studies suggested PGE2 promoted bone formation in specific dosage in vivo [12-14] and in vitro [15,16]. By adopting selective agonists and antagonists of EP4 receptor, researchers have found that PGE2 elevated the number of bone marrow osteogenic stromal cells, involved in differentiation and recruitment of osteoblasts, and exerted anti-apoptosis effect on periosteal cell line [17-20]. Moreover, EP4 receptor plays a crucial role in anabolic action on bone [12,13,16]. However, other studies indicated PGE2 could increase the number of osteoclasts [21] and EP4 receptor was expressed on osteoblasts but also was involved in osteoclasts differentiation [4]. Therefore, the exact role of PGE2 on bone metabolism seems to be unclear. It is worth noting that EP4 was the only functional receptors found in human osteoblasts in culture of the four receptors [22], which activated osteoblasts directly and osteoclasts indirectly [23]. Activation and increasing number of osteoclasts might associate with the new bone formed by osteoblasts [24]. The down expression of EP4 receptor in cholesteatoma suggested that bone anabolic action could be attenuated and the bone resorption process might correspondingly be exacerbated. On the other hand, decreased expression of EP4 receptor may aggravate the inflammation response, leading to the increase of inflammatory cells and chemokines such as CD4+ T cells [10] and TNF-α [9]. And cholesteatoma debris also promoted the expression of TNF-α in monocytes [25]. TNF-α is a widely accepted cytokine generated by monocytes and lymphocytes, which caused osteoclastic bone resorption. Therefore, we consider EP4 receptor played an important role in the bone destruction of acquired cholesteatoma. It could be expected that EP4 receptor may become a possible therapeutic target for bone destruction of this disorder, which needs to be explored by future studies.

In the present study, the expression of EP1, EP2, or EP3 receptors did not show significant differences between two groups. Several studies reported that EP1, EP2, and EP3 receptors were also involved in some inflammatory diseases. EP1 was highly expressed in eosinophilic chronic rhinosinusitis with nasal polyps [26]. EP3 receptor elicited histamine release to promote inflammatory swelling through mast cell [27] and mediated adhesion of mast cell to the Arg-Gly-Asp-enriched matrix [28]. EP1 and EP3 mainly played a proinflammatory effect in these studies. It also found that EP2 receptor agonists presented an anabolic action on bone (primarily through P38 mitogen-activated protein kinases pathway) and its intracellular transduction pathway was different from EP4 receptor (mainly by extracellular signal-regulated kinases signaling) [29]. The differential expression of the four receptors might result from the specific activation of the involved cell types and intracellular transduction pathway in different lesions. No difference in the expression of EP1–EP3 receptors in cholesteatoma and skin suggests that these receptors may not be associated with inflammatory and destructive pathologic process of this disorder. The pathophysiology function of PGE2 in acquired cholesteatoma might mediate mainly through EP4 receptor. More detailed intracellular signaling pathway needs to be further investigated.

In the present study, we demonstrated the cellular distribution of EP1–EP4 and their expression on the mRNA and protein level in acquired cholesteatoma. Reduced expression of EP4 receptor might play a crucial role in the inflammation and bone resorption processes of acquired cholesteatoma.

▪ E-prostanoid (EP) 1–4 receptors were examined in acquired cholesteatoma and ear canal skin.

▪ The expression of EP4 receptor was decreased in acquired cholesteatoma, but not EP1–EP3.

▪ Low expression of EP4 may promote the development of acquired cholesteatoma.